Skip to main content
Premium Trial:

Request an Annual Quote

BioWisdom, Amgen, InforSense, Crosslinks, Van Andel Research Institute, Definiens

Premium
Amgen to Use BioWisdom's Sofia Software
 
Amgen has signed a multi-year license agreement to use BioWisdom’s knowledge network software, BioWisdom said this week.
 
BioWisdom’s Sofia software is used to format large amounts of complex data that drug developers generate in their research. The Cambridge, UK-based firm said the software creates “Intelligence Networks,” which it defines as “a unique format of assertional metadata that liberates knowledge from structured and unstructured data, regardless of its original format.”
 
Financial terms of the agreement were not released.
 

 
Crosslinks Joins InforSense Partner Network
 
InforSense said this week that Dutch bioinformatics services firm Crosslinks has joined the InforSense Open Partner Network as a certified provider of its workflow technology.
 
Crosslinks is a spinoff from the Erasmus MC Department of Bioinformatics and provides analysis of genomics and proteomics data.
 
Through the alliance, Crosslinks becomes a preferred InforSense Services Provider in Europe for both academic and commercial customers. It also operates a demonstration center in the Netherlands for InforSense’s technology.
 
The InforSense platform will allow Crosslinks to fulfill “growing demand for large-scale, genome-wide analyses,” Crosslinks CEO Ronald Nanninga said in a statement. He said the firm would apply the technology to bioinformatics data analysis in research and diagnostic applications.
 

 
Children’s Memorial Research Center Licenses Van Andel’s XenoBase
 
The Van Andel Research Institute said this week that Chicago’s Children's Memorial Research Center has licensed its XenoBase software and database system under a multi-year agreement.
 
XenoBase was designed to collect and analyze molecular and clinical data to help researchers identify associations between diseases, biomarkers, and treatment outcomes. The institute said that physicians have used the platform “to match the molecular profile of tumors of late-stage cancer patients to the most effective therapy, based on molecular evidence.”
 
CMRC will use XenoBase to study the molecular and clinical basis for disease and to discover new therapeutics.
 
Financial terms of the agreement were not disclosed.
 

 
Montpellier Rio Imaging to Use Definiens' Image Analysis Software
 
Montpellier Rio Imaging will use Definiens’ high-content image analysis and data management technology at its lab in the Languedoc-Roussillon region of France, Definiens said this week.
 
MRI said it will use the technology in its automated offerings for cell-based assays and large-scale histopathology research.
 
Financial terms of the agreement were not released.

Filed under

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.